COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results
06/11/2025
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq [...]
Growth in revenue and operating profit
06/11/2025
Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 115.6 million in the [...]
Genmab Announces Financial Results for the Nine Months of 2025
06/11/2025
November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus) Genmab revenue increased 21% compared to [...]
Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025
06/11/2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025. Later on the same day, the company will host a presentation for investors and [...]
Channel Medsystems Surpasses 5,000 Cerene® Cryotherapy Procedures, Marking Milestone in Women’s Health Innovation
06/11/2025
SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, a commercial-stage women’s health company, announced today that more than 5,000 women have now been treated with the Cerene® Cryotherapy Device, [...]
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
06/11/2025
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression Bilateral kidney injection with [...]
LTC ACO Demonstrates Continued Strength, Completing All 2024 Provider Payments
06/11/2025
Top-Ranking Long-Term Care ACO Reaffirms Financial Strength and Operational Stability KENNETT SQUARE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LTC ACO , the nation’s most experienced Accountable Care Organization (ACO) [...]
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
06/11/2025
Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001) [...]
Porch Light Health Launches Advanced Drug Lab to Improve Patient Safety and Spot Dangerous Drug Trends in Our Communities
06/11/2025
FORT COLLINS, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, a leading outpatient substance use disorder treatment provider serving Colorado and New Mexico, announces the opening of its new drug toxicology [...]
Pennant Group to Participate in the 2025 Stephens Annual Investment Conference
06/11/2025
EAGLE, Idaho, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it [...]
PharmaCorp Announces Upsized C$20 Million Bought Deal Public Offering
06/11/2025
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, [...]
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
06/11/2025
Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced [...]
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06/11/2025
REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
06/11/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 6 [...]
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06/11/2025
REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma [...]
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
06/11/2025
$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to [...]
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
06/11/2025
In-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism Ra’anana, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a [...]
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
06/11/2025
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron ® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, [...]
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
06/11/2025
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and [...]

Pages